Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo((R))) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland.

Article Details

Citation
Copy to clipboard

Wiesli P, Schories M

Improved Glycemic Control with Insulin Glargine 300 U/mL (Toujeo((R))) in Patients with Type 2 Diabetes: Real-World Effectiveness in Switzerland.

Diabetes Ther. 2018 Dec;9(6):2325-2334. doi: 10.1007/s13300-018-0518-x. Epub 2018 Oct 9.

PubMed ID
30302721 [ View in PubMed
]
Abstract

INTRODUCTION: Insulin glargine 300 U/mL (Gla-300, Toujeo((R))) is a long-acting, once-daily basal insulin with improved-more stable and smoother-pharmacokinetic and pharmacodynamic profiles compared to insulin glargine 100 U/mL (Gla-100) and insulin degludec (IDeg). These properties have been shown to translate into an effective HbA1c reduction with the advantage of a lower risk of hypoglycemia in randomized controlled trials of Gla-300 versus Gla-100. In this study, we assessed the effectiveness and safety of Gla-300 under real-world conditions in Switzerland. METHODS: The prospective, observational, open-label, multicenter study TOP-2 explored the effectiveness of Gla-300 in adult patients with type 2 diabetes (T2D) uncontrolled (HbA1c 7.5-10%) on their previous basal insulin in Germany, Austria, and Switzerland. The primary endpoints were the percentages of patients achieving a fasting plasma glucose (FPG) of

DrugBank Data that Cites this Article

Drugs